Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.

You Browsed By:

You Searched For:




Moody's Investors Service

Min Ye
Managing Director - Regional Head Asia Pacific

Brian Cahill
Managing Director - Asia Pacific Corporates/Financial Institutions

Stephen Long
Managing Director - Asia Pacific Financial Institutions

Kei Kitayama
Managing Director - Structured Finance

Tom Byrne
Senior Vice President - Sovereign Risk Group

Debra Roane
Vice President, Senior Credit Officer - Sub Sovereign

Natalie Wells
Associate Managing Director - Head of Asia Pacific Relationship Management

Moody's Analytics

Noah Berliner
Director - Sales Manager

Client Services

Find An Analyst


Asia Pacific

The product image can not be displayed.


  • 26 May 2015
    • Australian banks' changes to lending criteria for residential investments are credit-positive
      The recent changes are credit positive because they lower the big four banks' exposure to a higher-risk loan segment. At the same time, it is likely that further initiatives will be required during 2015 to bring investment lending in line with regulatory guidelines, as well as to adjust lending criteria and capital levels to respond to the rising tail risks embedded in the banks' evolving housing portfolios…Press Release l Full Report
  • 19 May 2015
    • Australian life insurers' profits under pressure through 2016
      The higher number of policy lapses and rising claims seen for risk products will erode profitability. The situation largely reflects a combination of fundamental issues, including product mispricing and premium and commission structures. While the industry is responding to the problem through a working group sponsored by the Financial Services Council, the structural issues will take several years to resolve.…Press Release l Full Report
    • China’s removal of drug price caps will lead to pharmaceutical innovations, better product quality
      The reform — which will take effect on 1 June — along with other medical reforms being undertaken by the Chinese government, will benefit in particular, large Chinese pharmaceutical companies with strong R&D capacity and product strength. However, drug prices will remain pressured because of intense competition under the provincial drug tender system, given that the minimization of health care costs remains a government's priority.… Press Release l Full Report
Research coverage includes Australia, China, India, Japan, Thailand, Vietnam, among many others.  
Please refine your search by Market Segment to get corresponding Rating Activity and Watchlist
Complete Your Profile
Please complete your profile before submitting your comments.
We're Sorry
    © 2015 Moody's Investors Service, Inc., Moody’s Analytics, Inc. and/or their affiliates and licensors. All rights reserved.
    Regional Sites: